Xu Quan

Title: Xu Quan - Innovator in Pharmaceutical Compounds

Xu Quan is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit acetyl-CoA carboxylase (ACC). His work is crucial in addressing various diseases associated with ACC expression.

Latest Patents

Xu Quan holds a patent for a compound as an ACC inhibitor and its use. The patent discloses a class of compounds that serve as inhibitors of acetyl-CoA carboxylase. These compounds, which include isomers, pharmaceutically acceptable salts, solvates, crystals, or prodrugs, are designed to treat and prevent diseases such as fibrotic diseases, metabolic diseases, cancers, and tissue hyperplasia diseases. The compound demonstrates good inhibitory activity against ACC and shows promise as a therapeutic drug for these conditions.

Career Highlights

Xu Quan is associated with Nanjing Sanhome Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work has the potential to impact the treatment of serious health conditions, making him a valuable asset to his company and the broader medical community.

Collaborations

Xu has collaborated with notable colleagues, including Yong Wang and Liwen Zhao, to advance his research and development efforts. Their combined expertise contributes to the success of their projects and the potential for groundbreaking discoveries in the pharmaceutical field.

Conclusion

In summary, Xu Quan is a dedicated inventor whose work on ACC inhibitors holds great promise for treating various diseases. His contributions to the pharmaceutical industry are noteworthy and reflect his commitment to innovation and improving health outcomes.